10 September - 13 September 2023
SCI’s Fine Chemicals Group and RSC’s Biological and Medicinal Chemistry Sector
Churchill College, Cambridge, UK
SCI and RSC members will be able to register at discounted rates which are detailed on the fees section further down the page.
A number of places will be reserved for poster presenters and contributions are invited from the whole field of medicinal chemistry. To enable presenters to receive approval from their institutions, there will be early and final submission dates of 28 April and 7 July 2023 respectively. Download an abstract template here and submit to email@example.com.
Churchill College is an ideal venue for exhibitors. All refreshments, the exhibition and posters will be situated in a single area, ensuring excellent access to delegates throughout the meeting.
The exhibition will run alongside the conference during refreshment breaks and poster sessions. Those who wish to exhibit are encouraged to book early to avoid disappointment. Exhibition stands will be available to book via the registration page when registration opens, and the rate will include two stand staff and daytime refreshments.
For further details, please contact firstname.lastname@example.org
The discovery of sebetralstat, an oral, small molecule oral plasma kallikrein inhibitor to treat attacks of hereditary angioedema
Rebecca Davie, KalVista
Discovery of reversible highly potent and selective MAGL inhibitors
Uwe Grether, Roche
Discovery and first-time disclosure of NT-0796, a clinical phase NLRP3 inflammasome inhibitor for inflammation
David Harrison, NodThera
LMW inhibitors of IL-1β, from fragment hits to cellular PoC
Konstanze Hurth, Novartis Institutes for BioMedica
Discovery of LAS202051, a potent Acetyl-CoA Carboxylase (ACC) inhibitor for the topical treatment of acne
Jordi Bach Taña, Almirall
Discovery of a novel class of brain penetrant inhibitors of KRAS G12C
Jason Kettle, AstraZeneca
Fadaltran, a Selective Antagonist for the Peripheral AR alpha 2c Receptors: A New Option for the Treatment of Diabetic Foot Ulcers?
Carsten Schmeck, Bayer
Fragment-based drug discovery approaches to the development of protein-protein interaction inhibitors
Dr John Skidmore, The ALBORADA Drug Discovery Institute, University of Cambridge
Plasmepsin X inhibitors with in vivo antimalarial activity
Teresa de Haro Garcia, UCB
Discovery of VX-147 as a Targeted Therapy for APOL1‑mediated Kidney Disease’
Les Dakin, Vertex
Lessons Learnt building the GSK pan-BET bromodomain portfolio
Phil Humphreys, GSK
Gamma Secretase Modulator for the treatment of Alzheimer's Disease
Rosa Maria Rodriguez Sarmiento, Hoffman La Roche
SAGE-718, a compound in phase II for a variety of CNS indications. (NMDAR PAM)
Lenacapavir, a First-in-class Long-Acting HIV Capsid Inhibitor
Eda Canales, Gilead
Structure-based Discovery of GS-9770: The Road to a Novel, Unboosted, HIV Protease Inhibitor
Ana Z. Gonzalez, Gilead
Design and Discovery of MRTX0902: An Inhibitor of the SOS1:KRAS Protein-Protein Interaction
Chris Smith, Mirati
Discovery of EDI048, a GI-targeted soft-drug for the treatment of chronic pediatric cryptosporidiosis.
Joe Young, Novartis
Pre-clinical and clinical evaluation of NDI-034858
Silvana Leit, Nimbus
Malaria therapy based on plasmodium Phosphatidylinositol-4-kinase and host hemoglobin degradation pathway
Godwin Dziwornu, H3D
Positive allosteric modulators of the α7 nAChR for the treatment of cognitive disorders: Invention of MK-4334
Ian Bell, Merck US
In Silico Enabled Discovery of Potent, Selective and Brain-penetrant DLK Inhibitors for the Treatment of Neurodegenerative Diseases
Rachel Lagiakos, Schrodinger
Data-driven optimisation of azabenzimidazoles as mGluR2 modulators for CNS disorders
Dr Sarah Major, Evotec
Kevin Doyle, Cerevance
AI-driven Drug Discovery Delivers Phase 1/2 Clinical A2AR Antagonist
Thorsten Nowak, Exscientia
Discovery of PF-07817883: A next generation oral protease inhibitor for the treatment of COVID-19
Matthew Sammons, Pfizer
Andrew Bell, Myricx Pharma
Pre-clinical and clinical evaluation of NDI-034858
Godwin Dziwornu, H3D
Arginase inhibitors for the treatment of cancer
Scott Mlynarski, Astrazeneca
Substrate Reduction Therapy for the Treatment of Metachromatic Leukodystrophy
Hall of Fame winner - Karin Briner
Malcolm Campbell Prize Winner - Charles Coombes - Samuraciclib
Sunday 13:30 - 16:30
As part of the conference, we are pleased to offer the opportunity to participate in a Medicinal Chemistry Workshop which will take place on the Sunday afternoon.
The workshop is based on an interactive, team-based game that allows you to explore various aspects of the drug discovery process. Delegates will work together in teams with peers from other organisations and the learning experience will be facilitated by a dedicated and diverse team of experienced professional medicinal chemists from across the pharmaceutical industry. This is a great way to accelerate your learning curve in medicinal chemistry, learning from your peers and our experts and it’s a lot of fun to play!
This event will be of interest to early career scientists, typically with five years or fewer post-graduate experience in medicinal chemistry.
To register your interest, please click here. There is no additional charge associated with participation in the workshop but places are limited
Accommodation for 3 nights (Sun 10 Sept, Mon 11 Sept and Tues 12 Sept) is available to book on registration for the event, as follows:
Package 1 - Conference only, NO accommodation and NO dinners included
Package 2 - Conference + 3 nights STANDARD en-suite accommodation, including dinners
Package 3 - Conference + 3 nights SUPERIOR en-suite accommodation, including dinners
Packages 2 and 3 also include breakfast and attendance to three conference dinners as follows:
If you are booking Package 1 (no accommodation or dinners included), you can choose to book onto one or more of the evening dinners as optional extras.
If you require an extra night of accommodation above the 3 included in accommodation packages, please email email@example.com. This is subject to availability
Tel: +44 (0)20 7598 1561
|SCI/RSC* Member - £485
Non-member - £600
SCI/RSC** Student Member - £200
Undergrad/Postgrad Student*** (not a member of SCI/RSC) - £300
Optional on-site accommodation
Standard en-suite accommodation and dinners (3 nights) - £450
Superior en-suite accommodation and dinners (3 nights) - £495
* RSC members should enter the Event discount code EJRFChem221 and select “Guest Member” under the section Member type. Delegates will be contacted for their RSC membership number after successful registration.
** RSC student members should enter the Event discount code EJRFChem221S and select “Guest Member” under the section Member type. Delegates will be contacted for their RSC membership number after successful registration.
*** Students who are not a member of SCI/RSC should email firstname.lastname@example.org from their institution email address to request the relevant code to book for this event
All registrations will automatically receive a confirmation within 24 hours of registering for the event. Should you not receive written confirmation of your booking, please email email@example.com.
Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
A limited number of student bursaries are available as a contribution to the cost of registration fees, travel and accommodation. For more information and to receive an application form, please contact firstname.lastname@example.org.